Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Activation of T cells to the capsid of adeno-associated virus (AAV) serotype 2 vectors has been implicated in liver toxicity in a recent human gene therapy trial of hemophilia B. To further investigate this kind of toxicity, we evaluated T-cell responses to AAV capsids after intramuscular injection of vectors into mice and nonhuman primates. High levels of T cells specific to capsids of vectors based on AAV2 and a phylogenetically related AAV variant were detected. Vectors from other AAV clades such as AAV8 (ref. 3), however, did not lead to activation of capsid-specific T cells. Through the generation of AAV2-AAV8 hybrids and the creation of site-directed mutations, we mapped the domain that directs the activation of T cells to the RXXR motif on VP3, which was previously shown to confer binding of the virion to heparan sulfate proteoglycan (HSPG). Evaluation of natural and engineered AAV variants showed direct correlations between heparin binding, uptake into human dendritic cells (DCs) and activation of capsid-specific T cells. The role of heparin binding in the activation of CD8(+) T cells may be useful in modulating the immunogenicity of antigens and improving the safety profile of existing AAV vectors for gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the VP3 VIII variable region of AAV8 is not involved in HSPG recognition by the cell surface receptor57.”
From An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species (2024) · cites this paper as [57]
In the citing paper
“However, this does not apply here because AAV8 does not elicit a CD8+ T cell response against capsid in mice and because the vector dose was anyhow too low to generate such a response.25,66,67”
From TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling (2024) · cites this paper as [66]
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 1×
“dtd" [ ]> Activation of T cells to the capsid of adeno-associated virus (AAV) serotype 2 vectors has been implicated in liver toxicity in a recent human gene therapy trial of hemophilia”
BackgroundNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Self-citationSummerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406 · cited 1×
“Through the generation of AAV2-AAV8 hybrids and the creation of site-directed mutations, we mapped the domain that directs the activation of T cells to the RXXR motif on VP3, which was previously shown to confer binding of the virion to heparan sulfate proteoglycan (HSPG”
BackgroundClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Self-citationThe atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612 · cited 1×
“The VP3 protein comprises the structural backbone for the particle architecture as well as the majority of variable domains between AAV2 and AAV8 (refs”
BackgroundIdentification of a heparin-binding motif on adeno-associated virus type 2 capsids
Kern, A., Schmidt, K., Leder, C., Müller, O. J., Wobus, C. E., Bettinger, K., Von der Lieth, C. W., King, J. A., & Kleinschmidt, J. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.11072-11081.2003 · Cited by 380 · cited 1×
“Through the generation of AAV2-AAV8 hybrids and the creation of site-directed mutations, we mapped the domain that directs the activation of T cells to the RXXR motif on VP3, which was previously shown to confer binding of the virion to heparan sulfate proteoglycan (HSPG”
BackgroundOpie, S. R., Warrington, Agbandje-McKenna, M., Zolotukhin, S., & Muzyczka, N. (2003) · Journal of Virology · doi:10.1128/jvi.77.12.6995-7006.2003 · Cited by 364 · cited 1×
“Through the generation of AAV2-AAV8 hybrids and the creation of site-directed mutations, we mapped the domain that directs the activation of T cells to the RXXR motif on VP3, which was previously shown to confer binding of the virion to heparan sulfate proteoglycan (HSPG”
BackgroundAdeno-associated viruses undergo substantial evolution in primates during natural infections
Gao, G., Alvira, M. R., Somanathan, S., Lu, Y., Vandenberghe, L. H., Rux, J. J., Calcedo, R., Sanmiguel, J., Abbas, Z., & Wilson, J. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0937739100 · Cited by 323
Self-citationHalbert, C. L., Allen, J. M., & Miller, A. D. (2001) · Journal of Virology · doi:10.1128/jvi.75.14.6615-6624.2001 · Cited by 314 · cited 1×
“All members of AAVs from Clades A, C, D, E and F are missing the RXXR motif, and those that have been studied do not bind heparin with the avidity of AAV2 (ref”
BackgroundWilson, N. S., & Villadangos, J. A. (2005) · Advances in Immunology · doi:10.1016/s0065-2776(04)86007-3 · Cited by 176 · cited 1×
“Pathways by which this occurs begin with endocytotic or phagocytotic uptake followed by a series of proteolytic steps and eventual loading of peptides onto MHC class I complexe”
Background
Cited by
Items 201–208 of 208
Lim, H., Choi, S., Jeon, Y.-E., Park, H., Choi, Y., Elangovan, M., Lee, N. K., Kwon, S. J., & Chang, J. W. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153620
Theo, C. H., Sam, I., & Chan, Y. F. (2026) · Journal of Medical Virology · doi:10.1002/jmv.70888
“A possible explanation is that the high HS affinity virions are sequestered by HS on cellular surfaces, thereby promoting presentation of immunogenic epitopes to stimulate T‐helper cells and B cells to produce specific neutralizing antibodies against the virus (Figure 1A) [120–122].”
RNA-based therapies for dysferlinopathies
Philippi, S. (2014) · theses.fr (ABES) · doi:10.70675/36df5bbcz5825z4793za0f5zd1f36e3ab980
“…immune response has been detected to act against the AAV2 capsid after injection into murine muscle, but not against the AAV1 capsid that lack the VP3 heparan sulfate proteoglycan–binding motif identified immunogenic in the AAV2 capsid in mice (Vandenberghe et al., 2006; Lorain et al., 2008).”
BackgroundDevelopment of safe and efficient aav vectors for retinal gene therapy
Khabou, H. (2018) · theses.fr (ABES) · doi:10.70675/aa896663z9772z4d87z9bd1z247af1f0e3f1
Modification chimique d’AAV pour la thérapie génique
Leray, A. (2021) · theses.fr (ABES) · doi:10.70675/c33b1ba2z6c22z40e1z9a98z3ed26b698b7a
Etude des réponses T CD8+ après transfert de gène par rAAV ciblant le muscle
Jeanpierre, L. (2024) · theses.fr (ABES) · doi:10.70675/430aceacz50d2z426bz907dz876c55d1e935
Metadata
- Authors
- Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., Grant, R. L., Gao, G., & Wilson, J. M.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Wilson, James M
- ORCID
- Venue
- Nature Medicine
- Published
- 2006-07-16
- Volume
- 12
- Issue
- 8
- Pages
- 967-971
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2080951809
- Cited by
- 208
- References
- 17
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 7 · 2020: 4 · 2019: 6 · 2018: 5 · 2017: 9 · 2016: 3 · 2015: 15 · 2014: 6 · 2013: 14 · 2012: 7
- FWCI
- 12.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Science Foundation
- GlaxoSmithKline
- National Heart, Lung, and Blood Institute (P01-HL-05407)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK047757)
- National Institute of Biomedical Imaging and Bioengineering
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- AAV2, AAV capsid, T cell activation, heparin binding, heparan sulfate proteoglycans, VP3, dendritic cell uptake, CD8+ T cells, AAV8, hepatotoxicity, hemophilia B, non-human primates
- MeSH terms
- Dependovirus, Animals, Capsid, Dendritic Cells, Genetic Markers, Genetic Vectors, Cricetinae, HeLa Cells, Heparin, Humans, Interferon-gamma, Kinetics, Leukocytes, Mononuclear, Lymphocyte Activation, Macaca fascicularis, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Serotyping, T-Lymphocytes, Time Factors, Interleukin-4, Granulocyte-Macrophage Colony-Stimulating Factor, CHO Cells, Protein Structure, Tertiary, Capsid Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.